140 E. Ridgewood Avenue South Tower, Suite #415
About Epygenix Therapeutics
Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company developing drugs to treat rare and intractable genetic epilepsise, such as Dravet syndrome, Lennox- Gastaut syndrome, and etc.
7 articles about Epygenix Therapeutics
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer
Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable forms of genetic epilepsy, announces the appointment of Lorianne Masuoka, MD as Chief Medical Officer.
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
Clinical Catch-Up for February 21
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
Epygenix Therapeutics, Inc. announced that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to assess safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 in fasting healthy subjects and following a high-fat meal.
Epygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome
Epygenix Therapeutics Receives Orphan Drug Designation From The U.S. FDA For EPX-100 And EPX-200 In The Treatment Of Patients With Dravet Syndrome